Kentucky Governor Adds 15 Conditions to Medical Cannabis Program

Gov. Andy Beshear signed an executive order on June 2, 2026, directing the state’s Office of Medical Cannabis to issue an emergency regulation recognizing 15 new qualifying conditions under existing state law — a move he said could make more than 400,000 additional Kentuckians eligible for the medical cannabis program.

The action comes after repeated legislative failures to expand the qualifying conditions list. The Office of Medical Cannabis, the Team Kentucky Medical Cannabis Workgroup, and the state’s Board of Physicians and Advisors had all formally urged the General Assembly to act before the 2026 session ended. None of those requests produced legislation.

What the Order Covers

The emergency regulation adds terminal illness, sickle cell anemia, ALS, Parkinson’s disease, HIV, AIDS, Huntington’s disease, muscular dystrophy, cachexia or wasting syndrome, Crohn’s disease, ulcerative colitis, neuropathies, severe arthritis, fibromyalgia, and glaucoma to the recognized conditions list. Those 15 sit alongside the conditions covered since the law took effect in January 2025: cancer, chronic or severe pain, epilepsy and seizure disorders, multiple sclerosis, muscle spasms, chronic nausea, and PTSD.

Beshear framed the order as clarification, not new law. His argument: if the underlying medical cannabis statute covers conditions whose symptoms include chronic pain or nausea, then a patient whose diagnosed disease inherently causes those symptoms is already eligible — the emergency regulation just makes that eligibility explicit. A patient with sickle cell anemia experiences severe pain by definition. If pain qualifies, the disease driving it should too.

“Too much is at risk to just stand by and let the law’s lack of clarity leave Kentuckians without relief,” he said.

The Legislative Gap and the Legal Risk

The Office of Medical Cannabis sent a formal recommendation to legislative leadership on expanding qualifying conditions in February 2026. The General Assembly’s 2026 session came and went without acting on it. Multiple bills aimed at improving the medical program were introduced — including proposals to allow home cultivation, expand conditions, and offer employment protections for patients — but none received committee hearings.

With the legislature sidelined, Beshear moved through executive authority. That choice carries legal exposure. Asked whether the state attorney general would challenge the order, Beshear was dismissive, insisting the regulation clarifies what the existing law already covers rather than extending it. That framing is load-bearing: a regulation cast as clarification occupies different legal ground than an order openly creating new eligibility categories. If the attorney general disagrees and files a challenge, how courts read that distinction becomes the decisive question.

Kentucky’s program has grown steadily since sales launched. As of June 2, 2026, 32 licensed cannabis businesses are operating in the state, more than 500 medical professionals are authorized to recommend cannabis, and more than 23,700 Kentuckians have approved medical cannabis cards. The legalization law was signed in March 2023; the state’s first licensed dispensary didn’t open until December 2025.

Decriminalization and Federal Reform

Beshear used the announcement to call for reform beyond the order itself. On state policy, he said it was “time for decriminalization” — under current Kentucky law, cannabis possession outside the medical program is still a criminal offense carrying potential jail time, even for minimal amounts. On the federal side, he expressed support for the Trump administration’s ongoing effort to move cannabis to a lower-risk federal classification, a position he also held under the prior administration, while arguing that rescheduling falls short of what he considers necessary. “Nobody should be going to jail just because of marijuana,” he said.

Kentucky is among the states with no decriminalization law on its books. Even as the medical program has expanded, possession outside it remains criminal — a gap that patient advocates have consistently flagged.

Beshear has consistently cast Kentucky’s medical cannabis program as a tool for reducing opioid reliance, and the 15 newly recognized conditions strengthen that argument. Several — sickle cell anemia, ALS, severe arthritis — involve severe or chronic pain for which opioids are routinely prescribed. Federally funded research has linked regulated cannabis access to reductions in opioid overdose rates, a pattern documented in recent NIH-supported studies.

The pace of reform has picked up across states that have historically been slow to act. Louisiana recently extended cannabis access to terminally ill patients in hospital care — terminal illness is now one of the 15 conditions on Kentucky’s recognized list as well.

Whether the attorney general challenges the order determines how much of the potential gain materializes. If the emergency regulation survives legal scrutiny, Kentucky’s medical cannabis program could grow from fewer than 24,000 active participants to a pool of potential eligibility in the hundreds of thousands.